A new study from the University of Michigan Comprehensive Cancer Center suggests a class of drugs that has shown promise for breast and ovarian cancer patients with BRCA gene mutations may also benefit certain colorectal cancer patients, according to a U-M Health news report.
The class of drugs, called PARP inhibitors, fights against tumors with a specific mutation in the MRE11 gene. Approximately 15 percent of colorectal cancers have microsatellite instability, which is an error in the DNA. A large majority of these tumors have the MRE11 gene mutation, suggesting a broader application of PARP inhibitors.
Researchers found PARP inhibitors were even more effective when there are two copies of the MRE11 gene mutation. They are planning to launch a phase 1 clinical trial to test the utility of PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11.
Read the U-M Health release about PARP inhibitors in colorectal cancer.
Related articles on colorectal cancer:
Office Desk Jobs Double Colon Cancer Risk
Local Washington Health Board Reverses Approval of Colonoscopy Campaign
Coverage of Preventive Services Under New Healthcare Law Causing Confusion
The class of drugs, called PARP inhibitors, fights against tumors with a specific mutation in the MRE11 gene. Approximately 15 percent of colorectal cancers have microsatellite instability, which is an error in the DNA. A large majority of these tumors have the MRE11 gene mutation, suggesting a broader application of PARP inhibitors.
Researchers found PARP inhibitors were even more effective when there are two copies of the MRE11 gene mutation. They are planning to launch a phase 1 clinical trial to test the utility of PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11.
Read the U-M Health release about PARP inhibitors in colorectal cancer.
Related articles on colorectal cancer:
Office Desk Jobs Double Colon Cancer Risk
Local Washington Health Board Reverses Approval of Colonoscopy Campaign
Coverage of Preventive Services Under New Healthcare Law Causing Confusion